Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Septerna (SEPN) Other Accumulated Expenses (2023 - 2026)

Septerna's quarterly Other Accumulated Expenses came in at $363000.0 in Q1 2026, up 390.54% year-on-year from $74000.0 in Q1 2025, and up 145.27% quarter-over-quarter from $148000.0 in Q4 2025.

Septerna has reported Other Accumulated Expenses for 4 years, with the latest figure at $363000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Other Accumulated Expenses rose 390.54% year-over-year to $363000.0; the trailing twelve-month figure through Mar 2026 stood at $363000.0 (up 390.54% YoY), and the FY2025 full-year result was $148000.0, up 89.74% from the prior year.
  • Other Accumulated Expenses for Q1 2026 stood at $363000.0, up from $148000.0 in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $363000.0 in Q1 2026, with the low at $74000.0 in Q1 2025.
  • Average Other Accumulated Expenses over 4 years is $134625.0, with a median of $98500.0 recorded in 2023.
  • Year-over-year, Other Accumulated Expenses slipped 16.42% in 2025 and soared 390.54% in 2026.
  • Tracing SEPN's Other Accumulated Expenses over 4 years: stood at $85000.0 in 2023, then declined by 8.24% to $78000.0 in 2024, then surged by 89.74% to $148000.0 in 2025, then jumped by 145.27% to $363000.0 in 2026.
  • The last three Other Accumulated Expenses figures came in at $363000.0 (Q1 2026), $148000.0 (Q4 2025), and $112000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Septerna 1.34 Bn 1.34 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 363,000.00
Dec 31, 2025 148,000.00
Sep 30, 2025 112,000.00
Jun 30, 2025 83,000.00
Mar 31, 2025 74,000.00
Dec 31, 2024 78,000.00
Sep 30, 2024 134,000.00
Dec 31, 2023 85,000.00